{
  "symbol": "MO",
  "year": 2023,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2002,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.15
  },
  "top_positive": [
    {
      "sent": "44 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 2022 Reported $ 4,685 $ 1,611 $ 3,074 $ 1.69 NPM Adjustment Items (60) (15) (45) (0.02) Acquisition, disposition and integration-related items 10 2 8 \u2014 Tobacco and health and certain other litigation items 101 25 76 0.04 JUUL changes in fair value 1,355 \u2014 1,355 0.76 ABI-related special items 2,560 538 2,022 1.12 Cronos-related special items 180 8 172 0.09 Income tax items \u2014 33 (33) (0.02) 2022 Adjusted for Special Items $ 8,831 $ 2,202 $ 6,629 $ 3.66 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 2022 Reported $ 407 $ 183 $ 224 $ 0.12 Acquisition, disposition and integration-related items 1 \u2014 1 \u2014 Tobacco and health and certain other litigation items 43 11 32 0.02 JUUL changes in fair value 100 \u2014 100 0.06 ABI-related special items 2,507 527 1,980 1.10 Cronos-related special items 5 \u2014 5 \u2014 Income tax items \u2014 42 (42) (0.02) 2022 Adjusted for Special Items $ 3,063 $ 763 $ 2,300 $ 1.28 45 Table of Contents The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2023 and 2022: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 13.",
      "score": 0.9918
    },
    {
      "sent": "44 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 2022 Reported $ 4,685 $ 1,611 $ 3,074 $ 1.69 NPM Adjustment Items (60) (15) (45) (0.02) Acquisition, disposition and integration-related items 10 2 8 \u2014 Tobacco and health and certain other litigation items 101 25 76 0.04 JUUL changes in fair value 1,355 \u2014 1,355 0.76 ABI-related special items 2,560 538 2,022 1.12 Cronos-related special items 180 8 172 0.09 Income tax items \u2014 33 (33) (0.02) 2022 Adjusted for Special Items $ 8,831 $ 2,202 $ 6,629 $ 3.66 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 2022 Reported $ 407 $ 183 $ 224 $ 0.12 Acquisition, disposition and integration-related items 1 \u2014 1 \u2014 Tobacco and health and certain other litigation items 43 11 32 0.02 JUUL changes in fair value 100 \u2014 100 0.06 ABI-related special items 2,507 527 1,980 1.10 Cronos-related special items 5 \u2014 5 \u2014 Income tax items \u2014 42 (42) (0.02) 2022 Adjusted for Special Items $ 3,063 $ 763 $ 2,300 $ 1.28 45 Table of Contents The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2023 and 2022: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 13.",
      "score": 0.9918
    },
    {
      "sent": "44 Table of Contents The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the nine months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 8,193 $ 2,123 $ 6,070 $ 3.40 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 14 4 10 \u2014 Tobacco and health and certain other litigation items 424 106 318 0.18 Loss on disposition of JUUL equity securities 250 \u2014 250 0.14 ABI-related special items 54 11 43 0.02 Cronos-related special items 30 \u2014 30 0.02 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 8,950 $ 2,211 $ 6,739 $ 3.78 2022 Reported $ 4,685 $ 1,611 $ 3,074 $ 1.69 NPM Adjustment Items (60) (15) (45) (0.02) Acquisition, disposition and integration-related items 10 2 8 \u2014 Tobacco and health and certain other litigation items 101 25 76 0.04 JUUL changes in fair value 1,355 \u2014 1,355 0.76 ABI-related special items 2,560 538 2,022 1.12 Cronos-related special items 180 8 172 0.09 Income tax items \u2014 33 (33) (0.02) 2022 Adjusted for Special Items $ 8,831 $ 2,202 $ 6,629 $ 3.66 The following table provides a reconciliation of adjusted net earnings and adjusted diluted EPS for the three months ended September 30: (in millions of dollars, except per share data) Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS 2023 Reported $ 2,908 $ 742 $ 2,166 $ 1.22 NPM Adjustment Items (15) (4) (11) \u2014 Acquisition, disposition and integration-related items 13 4 9 \u2014 Tobacco and health and certain other litigation items 23 6 17 0.01 ABI-related special items 82 17 65 0.03 Income tax items \u2014 (29) 29 0.02 2023 Adjusted for Special Items $ 3,011 $ 736 $ 2,275 $ 1.28 2022 Reported $ 407 $ 183 $ 224 $ 0.12 Acquisition, disposition and integration-related items 1 \u2014 1 \u2014 Tobacco and health and certain other litigation items 43 11 32 0.02 JUUL changes in fair value 100 \u2014 100 0.06 ABI-related special items 2,507 527 1,980 1.10 Cronos-related special items 5 \u2014 5 \u2014 Income tax items \u2014 42 (42) (0.02) 2022 Adjusted for Special Items $ 3,063 $ 763 $ 2,300 $ 1.28 45 Table of Contents The following special items affected the comparability of statements of earnings amounts for the nine and three months ended September 30, 2023 and 2022: \u25aa NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 13.",
      "score": 0.9918
    }
  ],
  "top_negative": [
    {
      "sent": "(4) Includes as of October 23, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms \u201cLights\u201d and \u201cUltra Lights\u201d constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.",
      "score": -0.9517
    },
    {
      "sent": "(4) Includes as of October 23, 2023, one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms \u201cLights\u201d and \u201cUltra Lights\u201d constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.",
      "score": -0.9517
    },
    {
      "sent": "Plaintiffs\u2019 allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes.",
      "score": -0.9382
    }
  ],
  "forward_snippets": [
    "This guidance updates how an entity recognizes and measures contract assets and contract liabilities acquired in a business combination.",
    "This guidance requires that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program\u2019s nature, activity during the period, changes from period to period and potential magnitude.",
    "For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 14.",
    "New Accounting Guidance Not Yet Adopted .",
    "During the measurement period, we will adjust preliminary valuations assigned to assets and liabilities if new information is obtained about facts and circumstances that existed as of the NJOY Transaction date, that, if known, would have resulted in revised values for these items as of that date."
  ]
}